The VEGF/VEGFR Inhibitor Drugs Market is expected to register a CAGR of 7.90% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report presents an analysis based on product (fixed-height stretchers, adjustable stretchers, stretcher chairs). The report is segmented by type (non-motorized, motorized) and by application (bariatric stretchers, radiographic stretchers, pediatric stretchers, emergency and transport stretchers, procedural stretchers, ob/gyn (obstetrics and gynecology) stretchers). The report further provides analysis based on end user (hospitals, clinics, ambulatory surgical centers, community first aids, others). The global analysis is further broken-down at regional level and major countries. The market size and forecast at global, regional, and country levels for all the key market segments are covered under the scope. The report offers the value in USD for the above analysis and segments. The report provides key statistics on the market status of the key market players and offers market trends and opportunities.
Purpose of the ReportThe report VEGF/VEGFR Inhibitor Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
VEGF/VEGFR Inhibitor Drugs Market Segmentation
Type- Tyrosine Kinase Inhibitors
- Monoclonal Antibodies
- Others
- Oncology
- Ophthalmology
- Others
Strategic Insights
VEGF/VEGFR Inhibitor Drugs Market Growth Drivers- Growing Incidence of Cancer: Rising incidence of various cancers, including breast cancer, lung cancer, and pancreatic cancer, is an important growth driver for the VEGF/VEGFR inhibitor market. As cancer continues to be one of the significant causes of death worldwide, the need for successful anti-angiogenic therapies keeps growing and encourages market growth.
- Growth in Combination Therapies:The market growth is mainly driven by the trend of using combination therapies that combine VEGF/VEGFR inhibitors with other therapeutic approaches. Such strategies enhance their therapeutic benefits and patient outcomes and are increasingly adopted by oncologists and healthcare providers.
- Wider applications in ophthalmology:VEGF/VEGFR inhibitors are increasingly used for the treatment of diseases such as AMD and diabetic retinopathy in the field of ophthalmology. Because of their high prevalence rate, the demand for these treatments is expanding rapidly, which is helping increase the market for these inhibitors in ophthalmic applications
- Personalised Medicine:Growing interest in personalized medicine in oncology has led the development of designed therapies meant for specific profiles of patients. This is likely to make treatments involving VEGF/VEGFR inhibitors even more successful and have more satisfying results for the treatment for the patient.
- More Study in Biosimilars:Increased availability and affordability, in the context of biosimilars, are leading trends in the VEGF inhibitor market. The entry of biosimilars in the market will increase the accessibility and lower the cost for patients who require anti-angiogenic therapies when patents of the original biologics expire.
- Incorporation of Gene Therapy Concepts:New gene therapy techniques targeted on VEGF/VEGFR pathways are also becoming more prominent. Such techniques directly modify angiogenesis' genetic factors and enhance the efficacy of well-established treatments, and therefore, are also more feasible to become long-term solutions for patients.
- Advancement of novel inhibitors:Industries are free to explore further by designing next generation VEGF/ VEGFR inhibitors with better selectivity and less side effects. Current therapies have barrier which can be resolved through use of different molecular framework.
- Strategic Collaborations With Research Institutions.:Engaging in joint ventures with universities and research centers can considerably shorten the timeline for the research and engagement of new VEGF inhibitors. Such activities can facilitate the implementation of advanced studies for developing new solutions to existing problems in lead.
- Patient-oriented approach:Other than that, attention to customer’s education and support beside moderate service of therapy with inhibitors of VEGF is likely to improve compliance on the therapy. When these factors are considered as well as the ease of accessing treatment information, the users of the product will develop a sense of loyalty resulting to better treatment outcomes for the patients using the product offered by the manufacturers.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the VEGF/VEGFR Inhibitor Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the VEGF/VEGFR Inhibitor Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Based on application, the market is segmented as Oncology, Ophthalmology, Others. The Oncology segment is expected to hold the largest VEGF/VEGFR inhibitor drugs market share in 2023.
Pfizer, Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Bayer AG are some of the key players influencing the VEGF/VEGFR inhibitor drugs market.
North America is expected to hold the largest share in the global VEGF/VEGFR inhibitor drugs market.
The major factors driving the VEGF/VEGFR inhibitor drugs market are:
1. Growing Incidence of Cancer
2. Growth in Combination Therapies
The final report will duly include market size and projection estimates for all the segments from 2021 to 2031, along with a revenue share and compound annual growth rate (%) for the regional/country-wise market wherein 2021-2022 are the historic years, 2023 is considered to be the base year, and the forecast will be provided till 2031, along with CAGR (%)
The VEGF/VEGFR inhibitor drugs market is estimated to witness a CAGR of 7.90% from 2023 to 2031
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 VEGF Inhibitor Drugs Market - By Type
1.3.2 VEGF Inhibitor Drugs Market - By Application
1.3.3 VEGF Inhibitor Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. VEGF INHIBITOR DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. VEGF INHIBITOR DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. VEGF INHIBITOR DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. VEGF INHIBITOR DRUGS - GLOBAL MARKET OVERVIEW
6.2. VEGF INHIBITOR DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. VEGF INHIBITOR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. TYROSINE KINASE INHIBITORS
7.3.1. Overview
7.3.2. Tyrosine Kinase Inhibitors Market Forecast and Analysis
7.4. MONOCLONAL ANTIBODIES
7.4.1. Overview
7.4.2. Monoclonal Antibodies Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. VEGF INHIBITOR DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. OPHTHALMOLOGY
8.4.1. Overview
8.4.2. Ophthalmology Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. VEGF INHIBITOR DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America VEGF Inhibitor Drugs Market Overview
9.1.2 North America VEGF Inhibitor Drugs Market Forecasts and Analysis
9.1.3 North America VEGF Inhibitor Drugs Market Forecasts and Analysis - By Type
9.1.4 North America VEGF Inhibitor Drugs Market Forecasts and Analysis - By Application
9.1.5 North America VEGF Inhibitor Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States VEGF Inhibitor Drugs Market
9.1.5.1.1 United States VEGF Inhibitor Drugs Market by Type
9.1.5.1.2 United States VEGF Inhibitor Drugs Market by Application
9.1.5.2 Canada VEGF Inhibitor Drugs Market
9.1.5.2.1 Canada VEGF Inhibitor Drugs Market by Type
9.1.5.2.2 Canada VEGF Inhibitor Drugs Market by Application
9.1.5.3 Mexico VEGF Inhibitor Drugs Market
9.1.5.3.1 Mexico VEGF Inhibitor Drugs Market by Type
9.1.5.3.2 Mexico VEGF Inhibitor Drugs Market by Application
9.2. EUROPE
9.2.1 Europe VEGF Inhibitor Drugs Market Overview
9.2.2 Europe VEGF Inhibitor Drugs Market Forecasts and Analysis
9.2.3 Europe VEGF Inhibitor Drugs Market Forecasts and Analysis - By Type
9.2.4 Europe VEGF Inhibitor Drugs Market Forecasts and Analysis - By Application
9.2.5 Europe VEGF Inhibitor Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany VEGF Inhibitor Drugs Market
9.2.5.1.1 Germany VEGF Inhibitor Drugs Market by Type
9.2.5.1.2 Germany VEGF Inhibitor Drugs Market by Application
9.2.5.2 France VEGF Inhibitor Drugs Market
9.2.5.2.1 France VEGF Inhibitor Drugs Market by Type
9.2.5.2.2 France VEGF Inhibitor Drugs Market by Application
9.2.5.3 Italy VEGF Inhibitor Drugs Market
9.2.5.3.1 Italy VEGF Inhibitor Drugs Market by Type
9.2.5.3.2 Italy VEGF Inhibitor Drugs Market by Application
9.2.5.4 Spain VEGF Inhibitor Drugs Market
9.2.5.4.1 Spain VEGF Inhibitor Drugs Market by Type
9.2.5.4.2 Spain VEGF Inhibitor Drugs Market by Application
9.2.5.5 United Kingdom VEGF Inhibitor Drugs Market
9.2.5.5.1 United Kingdom VEGF Inhibitor Drugs Market by Type
9.2.5.5.2 United Kingdom VEGF Inhibitor Drugs Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific VEGF Inhibitor Drugs Market Overview
9.3.2 Asia-Pacific VEGF Inhibitor Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific VEGF Inhibitor Drugs Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific VEGF Inhibitor Drugs Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific VEGF Inhibitor Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia VEGF Inhibitor Drugs Market
9.3.5.1.1 Australia VEGF Inhibitor Drugs Market by Type
9.3.5.1.2 Australia VEGF Inhibitor Drugs Market by Application
9.3.5.2 China VEGF Inhibitor Drugs Market
9.3.5.2.1 China VEGF Inhibitor Drugs Market by Type
9.3.5.2.2 China VEGF Inhibitor Drugs Market by Application
9.3.5.3 India VEGF Inhibitor Drugs Market
9.3.5.3.1 India VEGF Inhibitor Drugs Market by Type
9.3.5.3.2 India VEGF Inhibitor Drugs Market by Application
9.3.5.4 Japan VEGF Inhibitor Drugs Market
9.3.5.4.1 Japan VEGF Inhibitor Drugs Market by Type
9.3.5.4.2 Japan VEGF Inhibitor Drugs Market by Application
9.3.5.5 South Korea VEGF Inhibitor Drugs Market
9.3.5.5.1 South Korea VEGF Inhibitor Drugs Market by Type
9.3.5.5.2 South Korea VEGF Inhibitor Drugs Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa VEGF Inhibitor Drugs Market Overview
9.4.2 Middle East and Africa VEGF Inhibitor Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa VEGF Inhibitor Drugs Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa VEGF Inhibitor Drugs Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa VEGF Inhibitor Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa VEGF Inhibitor Drugs Market
9.4.5.1.1 South Africa VEGF Inhibitor Drugs Market by Type
9.4.5.1.2 South Africa VEGF Inhibitor Drugs Market by Application
9.4.5.2 Saudi Arabia VEGF Inhibitor Drugs Market
9.4.5.2.1 Saudi Arabia VEGF Inhibitor Drugs Market by Type
9.4.5.2.2 Saudi Arabia VEGF Inhibitor Drugs Market by Application
9.4.5.3 U.A.E VEGF Inhibitor Drugs Market
9.4.5.3.1 U.A.E VEGF Inhibitor Drugs Market by Type
9.4.5.3.2 U.A.E VEGF Inhibitor Drugs Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America VEGF Inhibitor Drugs Market Overview
9.5.2 South and Central America VEGF Inhibitor Drugs Market Forecasts and Analysis
9.5.3 South and Central America VEGF Inhibitor Drugs Market Forecasts and Analysis - By Type
9.5.4 South and Central America VEGF Inhibitor Drugs Market Forecasts and Analysis - By Application
9.5.5 South and Central America VEGF Inhibitor Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil VEGF Inhibitor Drugs Market
9.5.5.1.1 Brazil VEGF Inhibitor Drugs Market by Type
9.5.5.1.2 Brazil VEGF Inhibitor Drugs Market by Application
9.5.5.2 Argentina VEGF Inhibitor Drugs Market
9.5.5.2.1 Argentina VEGF Inhibitor Drugs Market by Type
9.5.5.2.2 Argentina VEGF Inhibitor Drugs Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL VEGF INHIBITOR DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. VEGF INHIBITOR DRUGS MARKET, KEY COMPANY PROFILES
12.1. PFIZER
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. GLAXOSMITHKLINE PLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. SANOFI
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ASTRAZENECA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. BRISTOL-MYERS SQUIBB COMPANY
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE LTD
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MERCK AND CO., INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BAYER AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ELI LILLY AND COMPANY
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Pfizer
2. Novartis AG
3. GlaxoSmithKline plc
4. Sanofi
5. AstraZeneca
6. Bristol-Myers Squibb Company
7. F. Hoffmann-La Roche Ltd
8. Merck & Co., Inc.
9. Bayer AG
10. Eli Lilly & Company
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For